Monday, 2 November 2015

We are building the case for a role in B cells are we making a case for PLEX quackery

We have been demonstration how B cells clearly have a role to play in the pathogenesis of MS and some of that role is mediated through the production of antibodies. 

So the solution you say is simple get rid of the B cells that produce antibodies and as Steve Austin would say..."we have the technology" and but it will cost more than $6,000,000. There are anibodies that will deplete plasma cells, but can we get them into the CNS? Could we infused them? Do we need to do this.?

However whilst we have been showing that antibodies are bad we may create a new avenue for the scammers to make money and this is via PLEX, which is plasma exchange. 

So as you are having your microbiome transplanted why not cleanse the blood at the same time for a total detox.

You get your plasma exchanged and this will remove antibodies fom the system. It is clear that PLEX is useful for some people with MS.

keda KM, Lee DH, Fraser JA, Mirsattari S, Morrow SA.Plasma Exchange in a Patient with Tumefactive, Corticosteroid-Resistant Multiple Sclerosis. Int J MS Care. 2015 Sep-Oct;17(5):231-5. doi: 10.7224/1537-2073.2014-078.
Tumefactive multiple sclerosis (MS) is an aggressive form of MS that can be difficult to treat with standard therapies. In severe MS relapses, plasma exchange (PLEX) has shown some benefit, but reports of its use in patients with tumefactive MS are limited. This article describes the successful use of PLEX in a patient with tumefactive MS. A 46-year-old right-handed woman with a recent diagnosis of MS presented with drowsiness, dysarthria, horizontal nystagmus, and quadriparesis. Her brain magnetic resonance images demonstrated multiple tumefactive demyelinating lesions in the medulla, bilateral periventricular white matter, and corona radiata white matter. She was initially treated with a 10-day course of intravenous methylprednisolone without benefit; therefore, PLEX was initiated. After the second exchange, the patient started to improve and was discharged initially to rehabilitation and then home. She was started on disease-modifying therapy with natalizumab and did not experience further relapses but had slow clinical decline during the next year, which led to discontinuation of natalizumab treatment. PLEX may be used as second-line treatment in corticosteroid-resistant MS relapses, but there are limited reports of its use in patients with tumefactive MS. This patient presented with aggressive disease with multiple tumefactive lesions and did not respond to standard treatment with corticosteroids. PLEX was successful in improving her symptoms, allowing her to return home, although the disease progressed during the next year.

Plasmaphoresis is used where you remove antibodies however it does not remove the plasma cells and so the antibodies come straight back

3 comments:

  1. True, I personally know individuals who have made plasmapheresis that remained stable for a while but then had to start a DMT because the disease returned "with a vengeance" ... I was going to ask this in the most recent publications on B cells: how to remove the plasma cells of the CNS?

    ReplyDelete
  2. I'm glad that Team G is starting to acknowledge B-cells are important in MS. After all, this is how Copaxone shows its effectiveness:

    http://www.ncbi.nlm.nih.gov/pubmed/25264704

    Team G is late to the party, but they are jumping on the bandwagon.

    ReplyDelete
    Replies
    1. Yeah Copaxone and B cells how could I think it was affect T cells:-(

      Maybe that explains my EAE data thanks.

      Investigator in anti-B cell trials and members of the steering committee for B cell studies is jumping on the bandwagon:-).

      Delete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.